A carregar...
Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design
Recent clinical advances with chimeric antigen receptor (CAR) T cells have led to the accelerated clinical approval of CD19-CARs to treat acute lymphoblastic leukemia. The CAR T cell therapy is nevertheless associated with toxicities, especially if the CARs are not entirely tumor-specific. Therefore...
Na minha lista:
| Publicado no: | PLoS One |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5976165/ https://ncbi.nlm.nih.gov/pubmed/29847570 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0197349 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|